Analysts think KOD stock price could increase by 69%
Feb 12, 2026, 12:25 PM
1.00%
What does KOD do
Kodiak Sciences, a clinical-stage biopharmaceutical company based in Palo Alto, develops therapeutics for retinal diseases, including tarcocimab and KSI-501, using its innovative ABC Platform. The company went public on October 4, 2018, and employs 107 staff.
8 analysts think KOD stock price will increase by 68.82%. The current median analyst target is $38.76 compared to a current stock price of $22.96. The lowest analysts target is $2.02 and the highest analyst target is $52.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.